Effects on classic cardiovascular risk factors CVOTs on GLP-1RAs Data from the major CVOTs ELIXA, SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6, LEADER, REWIND, and AMPLITUDE-O [53, 54, 56, 59,60,61,62,63] support the overall safety of GLP-1RAs relative to major cardiovascular outcomes
NADPH oxidase subunit, gp91(phox) homologue, preferentially expressed in human colon epithelial cells
However, individual considerations regarding digestive tolerance and monitoring requirements should be discussed with your healthcare provider to ensure safe and effective treatment tailored to your specific medical history
Non-approved Therapies for Obesity Incretin-based Treatments Since the isolation of the peptide exendin-4 from Heloderma suspectum (Gila Monster) lizard venom in 1992 [25], several drugs that manipulate the incretin axis have been produced and approved for use in people with T2D including exenatide (2005), liraglutide (2009), lixisenatide (2013), albiglutide (2014, withdrawn 2017), dulaglutide (2014) and semaglutide (2017) [26]
GLP-1 analogue liraglutide enhances SP-a expression in LPS-induced acute lung injury through the TTF-1 signaling pathway
